Medicare drug coverage

Tremfya: 2027 Medicare Part D coverage

4,693 of 5,495 Part D plans (85%) list Tremfya on their 2027 formulary, down 5 points from 2026. 98% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Tremfya is number 77 by total Medicare Part D spending in 2024 ($619 million). Plans that list it most often put it on tier 5. Counts use 7 RxNorm products for this name.

Tremfya Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it4,997 (91%)4,693 (85%)-5 points
Prior authorization (of plans that list it)4,897 (98%)4,596 (98%)no change
Step therapy (of plans that list it)4 (0%)4 (0%)no change
Quantity limit (of plans that list it)4,691 (94%)4,429 (94%)no change
Any of the three (of plans that list it)4,897 (98%)4,596 (98%)no change
Not listed or restricted (of all plans)5,418 (98%)5,398 (98%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Tremfya formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1144 (3%)107 (2%)
Tier 21 (0%)0 (0%)
Tier 450 (1%)44 (1%)
Tier 54,802 (96%)4,542 (97%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 41 of them (1%) added prior authorization, step therapy, or a quantity limit for Tremfya, and 360 stopped listing it.

Tremfya: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 2027360 (8%)
Listed it in 2027, not in 202695 (2%)
Moved it to a higher tier42 (1%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit41 (1%)
Added at least one of the three41 (1%)
Removed at least one of the three8 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Tremfya off the formulary or list it with prior authorization, step therapy, or a quantity limit. Alabama ranks first at 100%, with 96% of its plans using prior authorization or step therapy; Maryland ranks last at 80%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Tremfya, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Alabama115100%96%no change
2Indiana140100%94%no change
3Tennessee157100%94%no change
4Missouri171100%94%no change
5Oklahoma81100%94%no change
6Florida549100%93%no change
7New Mexico68100%93%no change
8Illinois133100%91%no change
9Ohio173100%91%no change
10Kansas84100%90%no change
11Texas412100%90%no change
12Kentucky123100%90%no change
13Arkansas86100%90%no change
14North Carolina177100%89%no change
15Arizona148100%89%no change
16Louisiana126100%88%no change
17South Carolina91100%88%no change
18New Jersey74100%86%no change
19Iowa64100%86%no change
20Utah53100%85%no change
21Nebraska51100%84%no change
22Minnesota63100%84%no change
23Nevada100100%84%no change
24Connecticut54100%83%no change
25South Dakota30100%83%no change
26Mississippi105100%83%no change
27Maine52100%83%no change
28North Dakota26100%81%no change
29New Hampshire25100%80%no change
30West Virginia70100%80%no change
31Delaware43100%74%no change
32Montana27100%74%no change
33Michigan183100%72%no change
34New York215100%71%no change
35Idaho45100%71%no change
36Rhode Island29100%66%no change
37Vermont14100%64%no change
38Wyoming13100%62%no change
39Pennsylvania324100%59%no change
40Massachusetts92100%57%no change
41Alaska9100%44%no change
42Wisconsin9799%89%no change
43Washington11497%89%no change
44Virginia14596%88%no change
45Oregon9296%83%no change
46Georgia15195%83%no change
47Colorado10690%81%+3 points
48Hawaii5088%78%+1 point
49California39788%71%no change
50District of Columbia2186%62%-2 points
51Maryland4980%69%-5 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Tremfya off or restrict it.

Tremfya coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Humana Inc.88488%100%100%no change0
UnitedHealth Group, Inc.850100%100%100%no change0
Devoted Health, Inc.728100%100%100%no change0
CVS Health Corporation633100%100%100%no change0
Elevance Health, Inc.29494%100%100%no change0
Centene Corporation2680%none list it100%no change0
Health Care Service Corporation231100%100%100%no change0
Kaiser Foundation Health Plan, Inc.112100%14%14%no change0
Highmark Health987%100%100%no change0
SCAN Group85100%100%100%no change0
Alignment Healthcare USA, LLC770%none list it100%no change0
Guidewell Mutual Holding Corporation5569%100%100%no change0
Blue Cross Blue Shield of Michigan Mutual Ins. Co.43100%100%100%no change0
Molina Healthcare, Inc.43100%100%100%no change0
Corewell Health400%none list it100%no change0
Zing Health Consolidator, Inc36100%100%100%no change0
CAPITAL BLUE CROSS3523%100%100%no change0
Medica Holding Company31100%100%100%no change0
UPMC Health System300%none list it100%no change0
Universal Health Services, Inc.29100%100%100%no change0
MHH Healthcare, L.P.2623%100%100%no change0
Independence Health Group, Inc.25100%100%100%no change12
Point32Health, Inc.230%none list it100%no change0
BlueCross BlueShield of Tennessee22100%100%100%no change0
California Physicians' Service22100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Tremfya?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing